2 patents currently held
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2042. from the record
Of the 14 now held by other companies, 9 name Atai Therapeutics Inc. as their current owner, and 5 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2042
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jul 2042 · High confidence
Also notable
Ends May 2042 · High confidence
Systems, Devices, and Methods for Generating and Manipulating Objects in a Virtual Reality or Multi-Sensory Environment to Maintain a Positive State of a User
US 11,660,419
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2042.
New N,n-Dimethyltryptamine Salts and Crystalline Salt Forms
US 12,378,194
Granted 2025. Too new for citation comparison; protection runs to 2042.
Formerly held, still cited
Notable
Ends Apr 2042 · High confidence
The most cited patent in this portfolio, cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2042.
now held by Atai Therapeutics, Inc.
Also notable
Ends Jun 2042 · Medium confidence
The most cited patent in this portfolio, cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2042.
now held by Atai Therapeutics, Inc.
Also notable
Ends Oct 2042 · High confidence
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2042.
now held by Empathbio, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Systems, Devices, and Methods for Generating and Manipulating Objects in a Virtual Reality or Multi-Sensory Environment to Maintain a Positive State of a User (US 11,660,419) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,378,194 | New N,n-Dimethyltryptamine Salts and Crystalline Salt Forms In force · High confidence | In force | High confidence | |
| US 11,660,419 | Systems, Devices, and Methods for Generating and Manipulating Objects in a Virtual Reality or Multi-Sensory Environment to Maintain a Positive State of a User In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 14 patents in force now held by others · 6 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.